Decitabine in the treatment of myelodysplastic syndromes

Expert Review of Anticancer Therapy

Volumn 10, Issue 1, 2010, Pages 9-22

  Santos, Fabio P S ^a   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a   Issa, Jean Pierre ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Decitabine; Hypomethylating agents; Myelodysplastic syndromes

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 METHYLDEOXYCYTIDINE; AZACITIDINE; BUSULFAN; CARMUSTINE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYTARABINE; DEOXYCYTIDINE; DEPSIPEPTIDE; ENTINOSTAT; FLUDARABINE; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; LBH 0589; MELPHALAN; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; PANOBINOSTAT; ROMIDEPSIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BACTERIAL INFECTION; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BONE PAIN; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CYTOGENETICS; DIARRHEA; DISEASE CLASSIFICATION; DNA METHYLATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; LIVER DYSFUNCTION; LOW DRUG DOSE; LUNG EMBOLISM; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; REVIEW; SEPSIS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; VOMITING;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 74949095984     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.164     Document Type: Review

References (91)

1. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin. Proc. 81(1), 104-130 (2006).
2. Rollison DE, Howlader N, Smith MT et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112(1), 45-52 (2008).
3. Hamblin TJ. Epidemiology of the myelodysplastic syndromes. In: Myelodysplastic Syndromes Pathobiology and Clinical Management. Steensma DP (Ed.). Informa Healthcare, New York, USA 27-48 (2009).
4. Brunning RD, Orazi A, Germing U et al. Myelodysplastic syndromes/neoplasms, overview. In: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL et al. (Eds). IARC Press, Lyon, France 88-93 (2008).
5. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6), 2079-2088 (1997).
6. Malcovati L, Germing U, Kuendgen A et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J. Clin. Oncol. 25(23), 3503-3510 (2007).
7. Kantarjian H, O'Brien S, Ravandi F et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 113(6), 1351-1361 (2008).
8. Robertson KD. DNA methylation and human disease. Nat. Rev. 6(8), 597-610 (2005).
9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New Engl. J. Med. 349(21), 2042-2054 (2003).
10. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 20(1), 1-13 (2006).
11. Boumber YA, Kondo Y, Chen X et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 67(5), 1997-2005 (2007).
12. Brakensiek K, Langer F, Schlegelberger B, Kreipe H, Lehmann U. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br. J. Haematol. 130(2), 209-217 (2005).
13. Johan MF, Bowen DT, Frew ME, Goodeve AC, Reilly JT. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br. J. Haematol. 129(1), 60-65 (2005).
14. Quesnel B, Guillerm G, Vereecque R et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91(8), 2985-2990 (1998).
15. Voso MT, Scardocci A, Guidi F et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 103(2), 698-700 (2004).
16. Grovdal M, Khan R, Aggerholm A et al. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin. Cancer Res. 13(23), 7107-7112 (2007).
17. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20(1), 85-93 (1980). •• First paper describing the rationale for epigenetic therapy.
18. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr. Opin. Oncol. 20(6), 705-710 (2008).
19. Pliml J, Sorm F. Synthesis of 2-deoxy-dribofuranosyl-5-azacytosine. Collect. Czech. Chem. Commun. 29, 2576-2577 (1964).
20. Hubeek I, Stam RW, Peters GJ et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br. J. Cancer 93(12), 1388-1394 (2005).
21. Wiley JS, Jones SP, Sawyer WH, Paterson AR. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J. Clin. Invest. 69(2), 479-489 (1982).
22. Momparler RL, Derse D. Kinetics of phosphorylation of 5-aza-2′-deoxyycytidine by deoxycytidine kinase. Biochem.Pharmacol. 28(8), 1443-1444 (1979).
23. Chabot GG, Bouchard J, Momparler RL. Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem. Pharmacol. 32(7), 1327-1328 (1983).
24. Momparler RL. Pharmacology of 5-aza-2′-deoxycytidine (decitabine). Semin. Hematol. 42(3 Suppl. 2), S9-S16 (2005).
25. Bouchard J, Momparler RL. Incorporation of 5-aza-2′-deoxycytidine- 5′-triphosphate into DNA. Interactions with mammalian DNA polymerase a and DNA methylase. Mol. Pharmacol. 24(1), 109-114 (1983).
26. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl Acad. Sci. USA 81(22), 6993-6997 (1984).
27. Ghoshal K, Datta J, Majumder S et al. 5-aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 25(11), 4727-4741 (2005).
28. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393(6683), 386-389 (1998).
29. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J. Biol. Chem. 257(4), 2041-2048 (1982).
30. Wilson VL, Jones PA, Momparler RL. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action. Cancer Res. 43(8), 3493-3496 (1983).
31. Momparler RL, Bouchard J, Onetto N, Rivard GE. 5-aza-2′- deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation. Leukemia Res. 8(2), 181-185 (1984).
32. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5-aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 65(16), 7086-7090 (2005).
33. Daskalakis M, Nguyen TT, Nguyen C et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100(8), 2957-2964 (2002).
34. Jilani I, Kantarjian H, Gorre M et al. Hypomethylation therapy of decitabine in patients with myelodysplastic syndromes (MDS) induces apoptosis and reduces proliferation. Blood 106(11), (2005) (Abstract 371).
35. Yang AS, Doshi KD, Choi SW et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 66(10), 5495-5503 (2006).
36. Kim CH, Marquez VE, Mao DT, Haines DR, McCormack JJ. Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J. Med. Chem. 29(8), 1374-1380 (1986).
37. Cheng JC, Matsen CB, Gonzales FA et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl Cancer Inst. 95(5), 399-409 (2003).
38. Flotho C, Claus R, Batz C et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23(6), 1019-1028 (2009).
39. Karpf AR. Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. Curr. Opin. Mol. Ther. 9(3), 231-241 (2007).
40. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-aza-2′-deoxycytidine induces reversible genomewide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell. Biol. 28(2), 752-771 (2008).
41. Wang H, Zhao Y, Li L et al. An ATM- and Rad3-related (ATR) signaling pathway and a phosphorylation-acetylation cascade are involved in activation of p53/p21Waf1/ Cip1 in response to 5-aza-2′-deoxycytidine treatment. J. Biol. Chem. 283(5), 2564-2574 (2008).
42. Zhu WG, Hileman T, Ke Y et al. 5-aza-2′-deoxycytidine activates the p53/p21Waf1/ Cip1 pathway to inhibit cell proliferation. J. Biol. Chem. 279(15), 15161-15166 (2004).
43. Karpf AR, Moore BC, Ririe TO, Jones DA. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol. Pharmacol. 59(4), 751-757 (2001).
44. Jackson-Grusby L, Beard C, Possemato R et al. Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. Nat. Genet. 27(1), 31-39 (2001).
45. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl Acad. Sci. USA 91(25), 11797-11801 (1994).
46. Link PA, Baer MR, James SR, Jones DA, Karpf AR. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/ acute myelogenous leukemia. Cancer Res. 68(22), 9358-9366 (2008).
47. van Groeningen CJ, Leyva A, O'Brien AM, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 46(9), 4831-4836 (1986).
48. Cashen AF, Shah AK, Todt L, Fisher N, DiPersio J. Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother. Pharmacol. 61(5), 759-766 (2008). • Details the pharmacokinetics of decitabine when administered following the 3-day schedule in patients with myelodysplastic syndrome.
49. Chabot GG, Rivard GE, Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-aza-2′-deoxycytidine in rabbits and dogs. Cancer Res. 43(2), 592-597 (1983).
50. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-aza-2′- deoxycytidine in patients with acute leukemia. Pharmacol. Ther. 30(3), 277-286 (1985).
51. Rivard GE, Momparler RL, Demers J et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res. 5(6), 453-462 (1981).
52. de Lima M, Ravandi F, Shahjahan M et al. Long-term follow-up of a Phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer 97(5), 1242-1247 (2003).
53. Ravandi F, Kantarjian H, Cohen A et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a Phase I study. Bone Marow Transplant. 27(12), 1221-1225 (2001).
54. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64(4), 922-929 (1984).
55. Pinto A, Zagonel V, Attadia V et al. 5-aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. Bone Marow Transplant. 4(Suppl. 3), 28-32 (1989).
56. Koshy M, Dorn L, Bressler L et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96(7), 2379-2384 (2000).
57. Zagonel V, Lo Re G, Marotta G et al. 5-aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7(Suppl. 1), 30-35 (1993).
58. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11(Suppl. 1), S19-S23 (1997).
59. Wijermans P, Lubbert M, Verhoef G et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J. Clin. Oncol. 18(5), 956-962 (2000). • Phase II study of decitabine administered following the 3-day schedule.
60. Wijermans PW, Lubbert M, Verhoef G, Klimek V, Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann. Hematol. 84(Suppl. 1), 9-17 (2005).
61. Cheson BD, Bennett JM, Kantarjian H et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96(12), 3671-3674 (2000).
62. van den Bosch J, Lubbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2′-deoxycytidine (decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leukemia Res. 28(8), 785-790 (2004).
63. Lubbert M, Wijermans P, Kunzmann R et al. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br. J. Haematol. 114(2), 349-357 (2001).
64. Ruter B, Wijermans P, Claus R, Kunzmann R, Lubbert M. Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7. Blood 110(3), 1080-1082; author reply 1083 (2007).
65. Ravandi F, Issa J-P, Garcia-Manero G et al. Hypomethylating therapy in patients with AML and high-risk MDS and chromosome 5 and 7 abnormalities is associated with an improved outcome compared to conventional chemotherapy. Blood 112(11), (2008) (Abstract 2955).
66. Kantarjian H, Issa JP, Rosenfeld CS et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer 106(8), 1794-1803 (2006). •• Randomized Phase III trial that led to the approval of decitabine for therapy of patients with myelodysplastic syndromes.
67. Wijermans P, Suciu S, Baila L et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized Phase III study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood 112(11), (2008) (Abstract 226).
68. Issa JP, Garcia-Manero G, Giles FJ et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5), 1635-1640 (2004). • Phase I study that established the most effective dose of decitabine.
69. Kantarjian H, Oki Y, Garcia-Manero G et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1), 52-57 (2007). •• Randomized study that developed the 5-day schedule of decitabine.
70. Kantarjian HM, O'Brien S, Huang X et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 109(6), 1133-1137 (2007).
71. Steensma DP, Baer MR, Slack JL et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J. Clin. Oncol. 27(23), 3842-3848 (2009). • Multicenter study confirming the activity of the 5-day schedule of decitabine.
72. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26(37), 5310-5318 (2007).
73. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37), 5541-5552 (2007).
74. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21(1), 103-107 (1999).
75. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 74(5), 659-671 (2007).
76. Yang H, Hoshino K, Sanchez-Gonzalez B, Kantarjian H, Garcia-Manero G. Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leukemia Res. 29(7), 739-748 (2005).
77. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108(10), 3271-3279 (2006). • First published study of decitabine in combination with a histone deacetylase inhibitor.
78. Issa J-P, Castoro R, Ravandi-Kashani F et al. Randomized Phase II study of combined epigenetic therapy: decitabine vs. decitabine and valproic acid in MDS and AML. Blood 112(11), (2008) (Abstract 228).
79. Ravandi F, Faderl S, Thomas D et al. Phase I Study of suberoylanilide hydroxamic acid (SAHA) and decitabine in patients with relapsed, refractory or poor prognosis leukemia. Blood 110(11), (2007) (Abstract 897).
80. Kirschbaum M, Gojo I, Goldberg SL et al. Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Blood 112(11), (2008) (Abstract 3651).
81. Jabbour E, Giralt S, Kantarjian H et al. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9), 1899-1905 (2009).
82. De Padua Silva L, de Lima M, Kantarjian H et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marow Transplant. 43(11), 839-843 (2009).
83. Lubbert M, Bertz H, Ruter B et al. Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marow Transplant. 44(9), 585-588. (2009).
84. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood 113(3), 659-667 (2009).
85. Jabbour E, Garcia-Manero G, Shan J et al. Outcome of patients (pts) with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post decitabine failure. Blood 112(11), (2008) (Abstract 1659).
86. Borthakur G, Ahdab SE, Ravandi F et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk. Lymphoma 49(4), 690-695 (2008).
87. Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, Phase III study. Lancet Oncol. 10(3), 223-232 (2009).
88. Kumar A, List AF, Mhaskar R, Djulbegovic B. Efficacy of hypo-methylating agents in the treatment of myelodysplastic syndromes: a systematic review and meta-analysis of randomized Controlled Trials. Blood 112(11), (2008) (Abstract 3632).
89. Steensma D, Kantarjian H, Wijermans P. Clinical experience with different dosing schedules of decitabine in patients with myelodysplastic syndromes (MDS). J. Clin. Oncol. 27(15S), (2009) (Abstract 7011).
90. Blum W, Klisovic R, Liu S et al. Preliminary results of a Phase II study of low dose decitabine as a single agent in older patients (age ≥60) with previously untreated acute myeloid leukemia (AML). Blood 112(11), (2008) (Abstract 2957).
91. Cashen AF, Schiller GJ, O'Donnell MR et al. Preliminary results of a multicenter Phase II trial of 5-day decitabine as front-line therapy for elderly patients with acute myeloid leukemia (AML). Blood 112(11), (2008) (Abstract 560).